SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing renewed momentum driven by strong prescription data and positive sentiment surrounding the oral Wegovy rollout, which is being viewed as a strategic advantage against competitors. Investors are closely watching the upcoming earnings report, with community discussions heavily focused on the company's ability to maintain its market position through potential M&A and improved guidance.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened retail activity and speculative momentum driven by its integration into the broader Japanese blockchain and IoT data economy narratives. While the community is actively debating the potential impact of ecosystem expansions like Janction, sentiment remains divided between long-term holders accumulating positions and skeptics focused on historical price underperformance.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following a series of bullish analyst initiations that highlight its potential as a significant player in the African e-commerce market, despite recent price volatility and broader market uncertainty. Investors are closely monitoring the stock ahead of upcoming earnings, with active community discussions focused on the companys path to profitability and its strategic positioning as an emerging long-term growth opportunity.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is currently trending as investors debate the impact of the newly launched spot ETF and shifting institutional adoption metrics amidst persistent price volatility. While some community members remain optimistic about long-term RWA tokenization potential, others are actively voicing frustration over the asset's underperformance relative to broader market movements.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant downward pressure as investors weigh disappointing earnings guidance and the financial implications of its recent acquisition of Exact Sciences. The community is actively debating whether the current price levels represent a deep-value buying opportunity or a value trap amid ongoing litigation concerns and broader institutional de-risking within the healthcare sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders react to reports that FDA Commissioner Marty Makary may be replaced, a move widely interpreted by the community as a positive catalyst that could alleviate regulatory friction for the company's oncology pipeline. Investors are actively discussing the potential for smoother sBLA reviews and increased global expansion, fueling bullish sentiment despite recent volatility and ongoing legal disputes.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing significant momentum and retail interest as investors connect the company's specialized MRAM technology to broader AI memory and aerospace growth narratives. Market participants are actively debating the sustainability of this rapid move, with bulls pointing to recent defense contracts and low float as catalysts for a potential squeeze, while some skeptics express concerns over high valuations and technical resistance.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing intense community focus as traders debate the impact of shifting GLP-1 regulatory landscapes and upcoming earnings, with many viewing recent price volatility as a potential accumulation zone ahead of next week's report. The conversation is dominated by a divide between bears concerned about competitive pressure and potential margin compression, and bulls who are banking on strong growth guidance and the expansion of the company's platform to drive a major momentum reversal.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending following a successful IPO that saw significant interest due to its strategic backing by Amazon and its position as a key infrastructure player in the AI power-demand narrative. The community is actively debating the company's valuation compared to peers, with investors highlighting the company's industrial partnerships and proprietary TRISO fuel technology as major differentiators for long-term scalability.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is experiencing significant volatility as investors debate the impact of AI on the SaaS business model, fueling intense community discussion about whether the recent sell-off presents a deep-value buying opportunity or a structural shift in software demand. Sentiment remains sharply divided, with bulls pointing to robust earnings beats and a significant cash position to defend the floor, while bears argue that AI agents and alternative tools threaten the company's long-term competitive position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$JANX UBS downgrade. $57 to $15. Even they are tired of the lazy POS CEO here.

Naser A

StockTwits For Android 

Janux Therapeutics Inc

 UBS downgrade. $57 to $15. Even they are tired of the lazy POS CEO here.

MarketWarfare

@MarketWarfare how many years does it take to commercialise a drug? Looks like they are 9 years old and 4 years after the IPO. Why replace a founder/CEO now when they started getting help from BMY? New CEO could cause disastrous drug failure trying to accelerate the science.

StockTwits for iOS

 how many years does it take to commercialise a drug? Looks like they are 9 years old and 4 years after the IPO. Why replace a founder/CEO now when they started getting help from BMY? New CEO could cause disastrous drug failure trying to accelerate the science.